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Background: Netrin-1 and its receptor UNC5B play important roles in angiogenesis, embryonic development,
cancer and inflammation. However, their expression patttern and biological roles in bladder cancer have not been
well characterized. The present study aims to investigating the clinical significance of PKC α, netrin-1 and UNC5B in
bladder cancer as well as their association with malignant biological behavior of cancer cells.
Methods: Netrin-1 and UNC5B expression was examined in 120 bladder cancer specimens using
immunohistochemistry and in 40 fresh cancer tissues by western blot. Immunofluorescence was performed in
cancer cell lines. PKC α agonist PMA and PKC siRNA was employed in bladder cancer cells. CCK-8, wound healing
assays and flow cytometry analysis were used to examine cell proliferation, migration and cell cycle, respectively.
Results: Netrin-1 expression was positively correlated with histological grade, T stage, metastasis and poor prognosis
in bladder cancer tissues. Immunofluorescence showed elevated netrin-1 and decreased UNC5B expression in bladder
cancer cells compared with normal bladder cell line. Furthermore, cell proliferation, migration and cell cycle progression
were promoted with PMA treatment while inhibited by calphostin C. In addition, PMA treatment could induce while
calphostin C reduce netrin-1 expression in bladder cancer cells.
Conclusions: The present study identified netrin-1/UNC5B, which could be regulated by PKC signaling, was important
mediators of bladder cancer progression.
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Bladder cancer (BC) is one of the most deadly urological
malignant tumors and also the 2nd most common urologic
cancer [1]. In the US, BC is the ninth most common cause
of cancer-related mortality, and is the fourth most common
cancer in men. Most bladder cancers are initially non-
invasive and up to 15% will progress to muscle-invasive
carcinoma. Although treatment of bladder cancer has
been improved greatly, the mortality of this disease is
still increasing [2].
As the central hub of a variety of signal transduction
process, PKC involves in cell information transmission,
secretion, cell differentiation and proliferation. What’s
more, it participates in apoptosis and differentiation of
tumor cells. PKC α is one subtype of classic protein kinase
C, which is closely related to recurrence of bladder cancer* Correspondence: syliujiao@sohu.com
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reproduction in any medium, provided the or[3]. PKC α can promote proliferation, migration and
survival of cancer cells through the downstream signal
transduction pathways ERK1/2 and NF-κB [4]. Recent
research shows that activation, overexpression of PKC
α as well as suppressing or depletion of PKC α can
regulate the proliferation of cancer cells [5-7]. Thus it can
be seen that PKC α is closely related to the biological
behaviour of bladder cancer.
As a kind of proto-oncogene, Netrin-1 is the axon
guidance factor that attracts the most attention in the
family of dependence receptor [8]. Researches show that
netrin-1 can activate PKC α after combination with its
receptor, which may cause phosphorylation to promote
cancer cell proliferation, and then restrain cell proliferation
[9]. In recent years, netrin-1 has been found effective in
inhibiting apoptosis in lung cancer, advanced neuro-
blastoma, breast cancer and prostate cancer [10-13].
UNC5B is one of the dependence receptors of netrin-1.
Researches show that UNC5B is the downstream geneThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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RNA Can significantly inhibit apoptosis, thus concludes
that UNC5B plays a role of inducing apoptosis, and it is a
kind of tumor suppressor genes [14]. According to reports
in the literature, up-regulation of netrin-1transcripts can
antagonize apoptosis induced by UNC5B [15]. Since
PKC α, netrin-1and UNC5B play a significant role in
the process of tumor treatment. Therefore, study the
mechanisms of action of PKC alpha regulates netrin-1/
UNC5B-mediated survival pathway is of great significance.
In this study, we detect the expression of netrin-1/
UNC5B in the bladder cancer tissues as well as in the
bladder cancer cell line on both the RNA and protein
levels, we found that netrin-1/UNC5B was closely related
to the activation of PKC alpha state. Furthermore,
netrin-1/UNC5B was closely associated with bladder
cancer malignant pathological biological behavior. There-
fore, we need to validate that PKC α inhibits bladder cancer




One hundred and twenty bladder cancer tissues were
collected by the surgical resection in the First Affiliated
Hospital of China Medical University from 2008 to 2012.
Bladder cancer tissues and paired adjacent normal bladder
tissues were collected. None of patients underwent
chemotherapy, radiotherapy or adjuvant treatment before
surgery. Patients’ consent for the research use of tumor
tissue was obtained, and the research protocol was
approved by Ethical Committee at China Medical University.
We followed up all patients for the survival time by
consulting their case documents and telephoning.
Cell culture, treatment of cells with drugs and siRNA
Human BC cell lines SV, 5637, T24 and BIU-87 were
purchased from Cell Bank of Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences. They
were maintained in RPMI 1640, or DMEM medium
supplemented with 10% fetal bovine serum (FBS). Cells
were incubated at 37°C in 5% CO2.
For PMA treatment, cells were treated at the concen-
tration of 100 nmol/L for 24 hours. For calphostin C
treatment, cells were treated by using 100 nmol/L PMA
for 4 hours first, then 50 nmol/L calphostin C for 24 hours.
For siRNA transfection, Lipofectamine (Invitrogen) was
used. PKC siRNA sequences was as follows: forward, 5’
GUG CCA UGA AUU UGU UAC UTT 3’, reverse, 5’
AGU AAC AAA UUC AUG GCA CTT 3’.
Real-time PCR
Total cellular RNA was extracted from cells using the
RNeasy Plus Mini Kit (Qiagen). First strand of cDNAwas synthesized by using PrimeScript RT reagent kit
(Takara). Quantitative real-time polymerase chain reaction
(QPCR) was done using SYBR Green PCR Master Mix
(Applied Biosystems) in a total volume of 20 μl on a 7900
Real-Time PCR System (Applied Biosystems): 50°C for
2 min, 95°C for 5 min, 45 cycles of 95°C for 40 s, 60°C for
30 s. The sequences of the primer pairs are: UNC5B for-
ward, 5’ CAG GGC AAG TTC TAC GAG AT 3’, reverse,
5’ TGG TCC AGC AGG ATG TGA 3’, netrin-1 forward,
5’ GTC AAT GCG GCC TTC GG 3’, reverse, 5’ CTG
CTC GTT CTG CTT GGT GAT 3’, β-actin forward, 5’
TTA GTT GCG TTA CAC CCT TTC 3’, reverse, 5’ ACC
TTC ACC GTT CCA GTT T 3’, β-actin was used as
the reference gene. Relative gene expression levels were
represented as ΔCT =CT gene – CT reference; fold
change of gene expression was computed by the 2−ΔΔCT
method [16]. Experiments were repeated in triplicate.
Western blotting
Total protein from cells was extracted in lysis buffer
(Pierce) and quantified using the Bradford method. Total
protein was separated by SDS-PAGE (12%). After
transferring to polyvinylidene fluoride (PVDF) mem-
brane (Millipore, Billerica, MA), the membranes were
incubated overnight at 4°C with antibodies against UNC5B/
netrin-1 (1:1000, Abcam Inc. USA), GAPDH (1:500, Santa
Cruz Biotechnology). After incubation with peroxidase-
coupled anti-mouse/rabbit IgG (Santa Cruz Biotechnol-
ogy) at 37°C for 2 h, bound proteins were visualized using
ECL (Pierce) and detected using BioImaging Systems
(UVP Inc., Upland, CA). The relative protein levels were
calculated based on GAPDH protein as a loading control.
Immunohistochemistry and evaluation
Sections were deparaffinized in xylene, hydrated in graded
alcohols. After antigen retrieval, sections were incubated
in an aqueous solution of 3% hydrogen peroxide followed
by incubation with 5% non-fat milk, which served as a
blocking agent for nonspecific binding. Slides were incu-
bated with UNC5B & netrin-1 rabbit polyclonal antibody
with an optimal dilution of 1:100 overnight at 4°C.
Biotinylated goat anti-rabbit serum IgG was used as a
secondary antibody. After washing, the sections were
incubated with streptavidin–biotin conjugated with horse-
radish peroxidase at room temperature for 10 min, and
the peroxidase reaction was developed with 3, 3′-diamino-
benzidine tetrahydrochloride. All the slides were evaluated
by 2 pathologists. Five views were examined per slide; 100
cells were observed per view at × 400 magnification. Nu-
cleus and/or cytoplasmic immune-staining in tumor cells
were considered positively. Positive reactions were scored
for both intensity of staining and percentage of positive
cells. Intensity grades were 0 (no staining), 1 (weak, light
yellow), 2(moderate, yellowish brown), to 3 (intense,
Liu et al. BMC Cancer 2014, 14:93 Page 3 of 13
http://www.biomedcentral.com/1471-2407/14/93brown) and the percentage of positive tumor cells were
scored as 0 (negative), 1 (1–50%), 2 (51–75%), 3 (≥76%).
Scores of each sample were multiplied to give final
scores of 0–9, and the tumors were finally determined
as negative: score 0; low expression: 0 < score ≤ 4; or high
expression: score > 4.
Cell proliferation and invasion assays
Cell Counting Kit-8 (Dojindo) was employed to determine
the number of viable BIU cells. Experiments were per-
formed according the manufacturer’s protocol. Invasion
ability was examined by wound healing assay. In brief,
cells were seeded at a density of 1.0 × 106 cells/well in
6-well culture plates. After they grown into confluence,
scratch was performed using a pipette tip, cells were
washed with PBS and cultured in the FBF-free medium
for 24 hours and photographed.
Cell cycle by flow cytometry
Cells with different treatment were harvested, fixed in
1% paraformaldehyde, washed with phosphate-buffered
saline (PBS), and stained in 5 mg/ml propidium iodide
in PBS supplemented with RNase A (Roche, Indianapolis,
IN) for 30 minutes at room temperature. Data were
collected using BD systems.
Immunofluorescence
Cells were washed with PBS, fixed with 4% formalde-
hyde, permeabilized with 0.2% Triton X-100 at 37°C,
and incubated in 5% BSA. Then cells were incubated
with rabbit anti-human netrin-1 & UNC5B antibody
(1:100) and mouse anti-human PKC α antibody (1:50)
overnight at 4°C. Then fluorescently labeled goat anti-
rabbit IgG (1:200) were added at 37°C for 1 h. Nucleus
was stained with DAPI. Cells was then observed using
fluorescence microscope.
Statistical analysis
SPSS 13.0(SPSS Inc, Chicago, IL) was used for statistical
analysis. The χ2 test was used to evaluate the association
between the expression of netrin-1 & UNC5B and clinico-
pathologic variables. Kaplan-Meier method and log-rank
test were used for survival analysis. The t-test was used to
analyze the difference for western blot data. p values < 0.05
was considered significant.
Results
Expression of netrin-1 and UNC5B in bladder cancer
tissues and association between their expressions &
clinicopathologic parameters
Quantitative real-time PCR (RT-PCR) and western blot
analysis were used to evaluate netrin-1 & UNC5B expres-
sion in 120 BC tissues and 40 normal bladder epithelial
tissues. It showed that the increased netrin-1 expressionand decreased UNC5B expression could be detected in
BC samples compared with the normal bladder samples
(P < 0.05). The mRNA expression of netrin-1 was found
to be increased, while that of UNC5B decreased in the
BC tissues as compared with the normal bladder epithelial
tissues. The protein expression of netrin-1 and UNC5B
showed the same trend as that of mRNA expression, and
the optical density of all tumor (T) & normal (N) tissues
were measured and expressed graphically (Figure 1).
Differences of mRNA expression and protein levels in
different T stage (T1, T2, T3 & T4) and histological grade
(G1, G2 & G3) were significant (P < 0.05) (Figure 2).
The expression of netrin-1 protein in BC and normal
adjacent tissues was located in both cytoplasm and nucleus,
while UNC5B protein appeared to be located only in
cytoplasm (Figure 3). Elevated expression of netrin-1
and down-regulated level of UNC5B was observed in T4
tumors compared with normal adjacent tissues (P < 0.01).
To explore the relationship of netrin-1 over-expression
and UNC5B down-regulation in a large cohort of BCs, we
examined the correlation between the immunostaining
of netrin-1 & UNC5B and clinic-pathological features
including age, gender, tumor size, tumor grade, etc. There
was a statistically significant positive correlation between
UNC5B & netrin-1 expression and high grade, aggressive
stage and metastasis (Tables 1 and 2), the expression of
UNC5B was finally determined T/N < 0.5 as low ex-
pression & T/N > = 0.5 as normal expression and the
expression of netrin-1 was considered T/N > 2 as high
expression & T/N < = 2 as normal expression.
During follow-up period, 70.0% (21 of 30) of tumors
with high netrin-1 expression developed metastasis com-
pared with 5.6% (5 of 90) of tumors with low netrin-1
expression, (P < 0.01). Meanwhile, 43.2% (19 of 44) of
tumors with low UNC5B expression showed metastasis,
compared with only 9.2% (7 of 76) of tumors with high
UNC5B expression having metastasis (P < 0.01). There-
fore, high expression of netrin-1 and low expression of
UNC5B were positively associated with metastasis of
BC. Kaplan-Meier plots and log-rank tests showed that
patients with high netrin-1 expression and low UNC5B
expression in their tumor tissues had statistically signifi-
cant shorter survival rate compared with those with low
netrin-1 expression and high UNC5B expression (P < 0.01).
However, there was no significant association between
tumor recurrence and intense & feeble netrin-1 expression;
recurrence curve analysis also indicated that the difference
was not statistically significant with high & low UNC5B
expression (P > 0.01). Moreover, we found that patients
with high netrin-1 expression and low UNC5B expression
had statistically significant higher metastasis rate compared
with those with low netrin-1 expression and high UNC5B
expression (P < 0.01; Figure 4). Log-rank analysis also
showed that the expression of netrin-1 & UNC5B (P < 0.01)
Figure 1 Expression by RT-PCR and western blot in BC tissues (T) and normal bladder tissues (N). (A) The average netrin-1 & UNC5B
expression ± SD for all studied tumors (120 cases) and their corresponding normal tissues (40 cases) by RT-PCR, bar graphs describe significant
UNC5B down-regulation and netrin-1 up-regulation in T in comparison with N (P < 0.05), β-actin as an internal control. (B) UNC5B protein was
detected by western blot in 40 pair tissues and band intensities indicate UNC5B expression conspicuously lower in T comparing with N. GAPDH
was used as a loading control. (C) The ratio between the optical densities of UNC5B & GAPDH in the same tissue was calculated and expressed
graphically. Significant differences of UNC5B expression between T & N were analyzed statistically and UNC5B expression was obviously greater in
N (P < 0.05). (D) Netrin-1 protein was detected by western blot and increased in T. (E) The relative protein expression of netrin-1, GAPDH as an
internal control (P < 0.05).
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statistically significant independent association with poor
prognosis of the patients.
Netrin-1 & UNC5B expression and location in BC cell lines
Quantitative real-time PCR and western blot analysis
were used to evaluate the expression of netrin-1 & UNC5B
in human bladder cell lines SV, BIU-87, 5637 & T24, and
immunofluorescence was used to detect of netrin-1 &
UNC5B expression and localization. The results showed
that highly invasive BC T24 cells had stronger netrin-1
expression than the superficial BC BIU-87 & 5637 cells
and normal SV cells which had lowest expression. Op-
posite trend was observed regarding UNC5B expression
(Figure 5), It was further confirmed that the expression
of netrin-1 & UNC5B was positively correlated with BC
grade. Quantitative real-time PCR and western blot
analysis were also used to evaluate netrin-1 & UNC5B’s
expression after PMA (PKC α agonist) and calphostin
C (PKC α inhibitor) treatment. The results showed that
netrin-1 expression were significantly inhibited by cal-
phostin C and enhanced by PMA (treat for 24 h), while
UNC5B showed the opposite trend (Figure 6). Immuno-
fluorescence results showed that UNC5B was expressed
in BC cell cytoplasm in all these four cell lines, whilenetrin-1 was found mainly located in cell nucleus and
partly in cell cytoplasm (Figure 7).
BC cells treated with PKC α agonist & inhibitor & siRNA
PKC α inhibitor and agonist, PMA & calphostin C, were
applied to treat BC BIU cells. We found that cell prolif-
erative and invasive activities were significantly increased
after PMA treatment, but decreased by calphostin C
treatment (Figure 8). Moreover, the FCS showed that cell
cycle was accelerated by PMA treatment (S phase 22.33%
for 24 h, 36.41% for 48 h; G2/M phase 23.39% for 24 h,
34.42% for 48 h) and blocked by calphostin C treatment at
both S phase and G2/M phase (S phase 8.39% for 24 h,
4.92% for 48 h; G2/M phase 10.55% for 24 h, 7.46% for
48 h ) compared with BIU cell without drugs (S phase
13.14%; G2/M phase 16.72%) (Figure 9); the cells mainly
concentrated in G1/G2 phase (almost the same percentage
at 57.19%) from mitotic completion to DNA replication.
Migration of bladder cancer cells by wound healing.
Cells were seeded at 1.0 × 106 cells/well in 6-well plates.
After grown to confluence, the cell monolayer in each
well was scraped with a pipette tip to create a scratch.
Cells were washed by PBS three times and cultured in
the FBS-free medium. Cells were photographed after
24 h and the scratch area was measured using Image
Figure 2 Expressions by RT-PCR and western blot in different stages and grades. (A) UNC5B expression was different in BC specimens with
different clinical pathological stages (T1, T2, T3 & T4) at mRNA level. Data was analyzed by Student’s t test and shown as mean ± SD of ten
independent experiments. UNC5B expression in stage T4 was much less than in T1–T3 stages (P < 0.05). *P < 0.05 compared with stage T1 BC
tissues (paired t-test). (B) Different expressions of UNC5B in pT stage were detected by western blot and UNC5B expression in stage T4 was
sharply less than in T1–T3 stages (P < 0.05). (C) UNC5B mRNA expression was determined by RT-PCR in different grades (G1, G2 & G3). Differences
at G1 & G3 were significant. *P < 0.05 compared with G1 BC tissues (paired t-test). (D) Netrin-1 expression was different in BC specimens with
different pT stage at mRNA level by RT-PCR. Stage T4 was more than in T1–T3 stages (P < 0.05). (E) Western blot was used to detect netrin-1
expression in different stages. The band intensities indicate netrin-1 expression more in stage T4. (F) Netrin-1 expression was determined by
RT-PCR in different grades (G1, G2 & G3), and G3 was the highest (P < 0.05). *P < 0.05compared with G1 BC tissues (paired t-test). All data are
representative of 3 individual experiments.
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bladder cancer cells T24 & BIU-87 transiently. Real-time
PCR showed that, netrin-1 expression was elevated after
transfection with PKC siRNA, while UNC5B expression
was decreased (Figure 11). The immunofluorescence
confirmed the co-localization of PKC α and UNC5B,
suggesting that the presence of their endogenous binding
(Figure 12).
Discussion and conclusions
Protein Kinase C (PKC), as the hub of a variety of signal
transduction process, is not only involved in cell commu-
nication, secretion, cell differentiation & proliferation, but
more importantly involved in tumor cell apoptosis and
differentiation. PKC α is a classical Protein of Kinase C
isoforms. Our and others’ research have shown that PKC
α of high activation status is closely related to activation
and apoptosis of bladder cancer recurrence [3]. UNC5B
is abnormally expressed and associated with a highly
malignant, chemotherapy-related and poor prognosis incolon cancer. It was reported that netrin-1 binding to
its receptor can activate PKC α and lead to tumor cell
proliferation, but it did not clarify PKC α and netrin-1/
UNC5B’s regulatory mechanisms. To this end, we ex-
plored the mechanism of PKC α with netrin-1/UNC5B
in bladder cancer. Our work shows that, PKC α,
netrin-1 & UNC5B is closely related to the degree of
malignancy and progress in bladder cancer and found
PKC α promoted the survival of bladder cancer cell po-
tentially through netrin-1/UNC5B signaling pathway.
Thus, PKC α has an important influence on netrin-1/
UNC5B signaling pathway & bladder cancer’s occurrence
and development.
The expressions of netrin-1/UNC5B were detected in
bladder cancer tissues & adjacent tissues and the relevance
and the relationship with clinic pathological parameters
was analyzed. The results showed that UNC5B had higher
expression in adjacent tissues than bladder cancer tissues
and it had higher expression in the low-level cancer tis-
sues than in high-level ones, but netrin-1 in the opposite.
Figure 3 Representative images from immunohistochemical staining in different histological stages UNC5B was localized at cytoplasm
and netrin-1 was mainly in cell nucleus and partly in cell cytoplasm of tumor tissues with granular brown staining. Almost all T1 tumor
tissues showed strong UNC5B staining intensity. UNC5B expression in stage T4 was significantly less than in stage T1–T3 specimens (Figure 3A, B,
C & D) (P = 0.021). While netrin-1 showed strong expression in stage T4 than other stages (T3, T2 & T1) and was associated significantly with pT
stage (Figure 3E, F, G & H) (P = 0.013). Representative tissue sections with different immunointensity of UNC5B protein in A T1, B T2, C T3 & D T4.
E Low level of netrin-1 expression in T1, H High level of netrin-1 expression in T4, F & G represent T2 &T3. Magnification × 400. *P < 0.05 compared
with stage normal bladder tissues (paired t-test).
Table 1 Relationship between the expression of UNC5B
and clinicopathologic factors in BC patients
Factors Group UNC5B expression X2 P value
High(%) Low(%)
Gender Male 52(43.3%) 25(20.8%) 0.029 0.162
female 29(24.2%) 14(11.7%)
Age at surgery <55 29(24.2%) 18(15.0%) 2.152 0.247
≥55 44(36.6%) 29(24.2%)
Histologic grade G1 18(15.0%)) 5(4.2%) 7.537 0.032
G2 49(40.8%) 15(12.5%)
G3 17(14.2%) 16(13.3%)




Tumor size(mm) <10 16(13.3%) 5(4.2%) 2.011 0.436
10-30 32(26.7%) 24(20.0%)
>30 18(15.0%) 25(20.8%)
Multiplicity Unifocal 28(23.3%) 24(20.0%) 1.593 0.312
Multifocal 39(32.5%) 29(24.2%)
Recurrence Yes 39(32.5%) 43(35.8%) 31.573 0.220
No 14(11.7%) 24(20.0%)
Metastasis Yes 7(5.8%) 19(15.8%) 13.253 0.001
No 69(57.5%) 25(20.9%)
Table 2 Relationship between the expression of netrin-1
and clinicopathologic factors in BC patients
Factors Group Netrin-1 expression X2 P value
High(%) Low(%)
Gender Male 49(40.9%) 28(23.3%) 0.037 0.213
female 28(23.3%) 15(12.5%)
Age at surgery <55 24(20.0%) 23(19.2%) 1.984 0.198
≥55 25(20.8%) 48(40.0%)
Histologic grade G1 3(2.5%) 20(16.7%) 7.632 0.024
G2 38(31.6%) 26(21.7%)
G3 29(24.2%) 4(3.3%)




Tumor size(mm) <10 5(4.2%) 16(13.3%) 1.794 0.153
10-30 32(26.7%) 24(20.0%)
>30 24(20.0%) 19(15.8%)
Multiplicity Unifocal 26(21.7%) 26(21.7%) 1.782 0.264
Multifocal 32(26.6%) 36(30.0%)
Recurrence Yes 52(43.3%) 30(25.0%) 32.236 0.658
No 24(20.0%) 14(11.7%)
Metastasis Yes 21(17.5%) 5(4.2%) 10.896 0.002
No 9(7.5%) 85(70.8%)
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Figure 4 Survival, recurrence and metastasis curve analysis by the Kaplan-Meier method. (A) Patients with intense netrin-1 expression had
significantly shorter median survival time (76.624 months) than those with weak netrin-1 expression (117.981 months) through log-rank univariate
analysis (n = 120, P < 0.01). (B) Patients with weak UNC5B expression had significantly shorter median survival time (96.881 months) than those
with intense UNC5B expression (128.939 months) (P < 0.01). (C) Recurrence curve analysis indicated that the difference was not statistically significant
with intense netrin-1 expression (74.463 months) and lower expression (79.505 months). (P > 0.01) (D) The difference was not statistically significant in
more (84.47 months) and less (69.225 months) UNC5B expression by recurrence curve analysis. (P > 0.01) (E) Patients with intense netrin-1 expression
had significantly shorter median metastasis time (100.836 months) than those with weak netrin-1 expression (124.946 months). (P < 0.01) (F) Patients
with weak UNC5B expression had significantly shorter median metastasis time (71.243 months) than those with intense UNC5B expression
(125.957 months). (P < 0.01)
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UNC5B expression in the cytoplasm and netrin-1 existing
in the cytoplasm and nucleus; netrin-1’s expression
gradually increased from the bladder mucosa - transitional
cell carcinoma and high - grade cancer evolution, while
UNC5B is gradually reduced; netrin-1/UNC5B high/low
expression is closely related to bladder cancer clinicalgrading, staging & metastasis; and Pearson correlation
analysis showed that netrin-1 and UNC5B are negatively
correlated. Netrin-1/UNC5B’s expression is proved to
exist in kidney cancer and prostate cancer [13,17], and
found that netrin-1 inhibits apoptosis in lung cancer,
with advanced neuroblastoma, breast cancer [10-12];
UNC5B is one of the dependent receptors of netrin-1,
Figure 5 Expressions by RT-PCR and western blot in bladder cell lines. (A) Netrin-1 & UNC5B mRNA expression in four bladder
cell lines (T24, SV, 5637, and BIU-87) was assayed using quantitative real-time PCR. To normalize Netrin-1 & UNC5B expression, β-actin
was used as internal control. Each expression level was shown as mean + SD. UNC5B expression was significantly greater in SV cells
than in 5637, T24 or BIU-87, while netrin-1 was lower in SV than in BC cell lines. *P < 0.05 compared with BC cell lines including 5637,
T24 and BIU-87 (paired t-test). (B) UNC5B & (D) Netrin-1 expression at protein level in different cell lines (SV, BIU, 5637 and T24) were
analyzed by western blots with 50 μg protein extracts. GAPDH was selected to be endogenous control. The differences in UNC5B
expression between 5637, T24 and BIU-87 were significant. SV cells represent bladder normal cell lines of which UNC5B expression
is the most, the others are BC cell lines, and netrin-1 expresses the least in SV. (C) & (E) The ratio between the optical density of
UNC5B & netrin-1 and GAPDH of the same tissue was calculated and expressed graphically (P < 0.05). *P < 0.05 compared with BC cell
lines (paired t-test).
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netrin-1 transcription can antagonize UNC5B induced
apoptosis [15], which is consistent with the results of
this study. Previously we have confirmed that PKC α
is closely related to bladder cancer cell’s apoptosis &Figure 6 Expressions by RT-PCR and western blot in bladder cells
used to evaluate netrin-1 & UNC5B’s expression in treatment of cells (B
α inhibitor). The results showed that the cells were significantly inhibit
by PMA (24 h), and cells were first promoted, and then inhibited by P
(C) Confirmation of netrin-1 down-regulation with calphostin C and up
expression of netrin-1 & UNC5B in treatment of cells with drugs, GAPD
line BIU (paired t-test).recurrence [3], and that netrin-1’s binding to its re-
ceptor UNC5B can cause PKC α phosphorylation and
promote cancer cell proliferation [9], but it had not
been confirmed in bladder cancer, for which we had done
further research.with drugs. (A) & (B) Quantitative real-time PCR (RT-PCR) were
IU & SV) with drugs- PMA (PKC α agonist) and calphostin C (PKC
ed by calphostin C (24 h) in netrin-1’s expression and promoted
MA (4 h) then calphostin C (24 h). Whlie UNC5B was opposite.
-regulation with PMA by western blot. (D) The relative protein
H as an internal control (P < 0.05). *P < 0.05 compared with BC cell
Figure 7 Detection of UNC5B expression by immunefluorescence in four cell lines (SV, BIU, 5637 & T24) (A & E) SV, (B & F) BIU, (C & G)
5637, (D & H) T24. (A, B, C & D) The expression of UNC5B located in cytoplasm (red color). The blue ones were cell nucleolus. Other ones are
transmission light figures. From these figures we can see cells’ form clearly. UNC5B location was almost the same in SV, 5637, T24 & BIU-87 bladder
cancer cells lines. (E, F, G & H) The localization in four cell lines (SV, BIU, 5637 & T24) of netrin-1 was found by immunofluorescence mainly in cell
nucleus and partly in cell cytoplasm.
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http://www.biomedcentral.com/1471-2407/14/93From the cellular level, it revealed netrin-1/UNC5B’s
expression & location in bladder carcinoma. Four kinds
of bladder cancer cell line T24, BIU-87, 5637 and SV
malignancy has been clearly stated in previous studies:
BIU-87, 5637, T24 are all bladder carcinoma cells, and
their degree of malignancy increased in turn, and
SV-HUC-1 is normal urothelial line [18]. We detected
netrin-1/UNC5B expression in bladder cancer cell line
from RNA and protein levels by Real-time PCR &
Western-blot ion, UNC5B’ expression was the highest
in normal bladder cell line (SV), and the expression
was the lowest in the most malignant cells of T24,
netrin-1 was the opposite. Immunofluorescence resultsshowed that UNC5B was in bladder cancer pulp while
expressions of netrin-1 existed in the cytoplasm and
the nucleus. Netrin-1/UNC5B’s expression in cells and
tissues shows consistent trend, and are related with the
degree of malignancy of bladder cancer cell lines. PKC
α has been shown to be involved in tumor cell apop-
tosis and differentiation. The high expression of PKC α
in bladder cancer cells was found to promote cancer
cell proliferation, and inhibit apoptosis and differenti-
ation [3].
When bladder cancer cell was given PKC inhibitors
and activators, and detected changes of netrin-1/UNC5B
expression and bladder cell cycle, proliferation and
Figure 8 Proliferation and invasion ability of BIU were inhibited by calphostin C and promoted by PMA. (A) CCK-8 assay was
used to examine BIU cell proliferation. cell proliferation was inhibited on dose-dependent correlation with the increasing concentration
(1, 3, 5, 7 μmol/L) of calphostin C at 24 h, 48 h, 72 h. (B) Cell proliferation was promoted by PMA on correlation with the increasing
concentration (50, 100, 200, 400 nmol/L) at 24 h, 48 h, 72 h. (C) According A450 of BIU at different times, cell proliferation curve was
drawn. Compared with BIU, cells with calphostin C were inhibited and cells with PMA were promoted. (D) & (E) According the optical
density value (A) of each well measured, BIU cell growth inhibition/activation ratio was calculated as (1 – A450 of experimental well/A450
of blank control well) × 100%, with different concentration of PMA (50, 100, 200, 400 nmol/L) and calphostin C (1, 3, 5, 7 μmol/L), we
calculated the activation/inhibition ratio. Each data are representative of 3 individual experiments. IC50 of calphostin C =7.4 μmol/L, and
IC50 of PMA = 24 nmol/L.
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http://www.biomedcentral.com/1471-2407/14/93apoptosis; it can be further confirmed that netrin-1/
UNC5B are closely related with PKC α activation.
When bladder cancer cell BIU-87 was given PKC in-
hibitors (calphoatin C) and activators (PMA), Real-
time PCR & Western-blot showed that netrin-1 was
inhibited after inhibitor treatment, while UNC5B was
activated; netrin-1 was activated after PMA treatment,
while UNC5B was suppressed. When CCK-8 and flow
cytometry detection was carried out after drug treat-
ment on bladder cancer cycle, proliferation and apop-
tosis. CCK-8 was found in best status by calphoatin C
or PMA for 48 hours, and the inhibition rate & the
activation rate increased with the increasing concen-
tration, and at the same time it can be drawn thatcalphostin C of IC50 = 7.4 μmol/L, PMA’s IC50 =
24 nmol/L. Flow cytometry showed S and G2/M were
inhibited or activated after calphoatin C or PMA treatment
BIU in better condition after 48 hours. These results
could confirm that netrin-1/UNC5B was closely associated
with PKC α activation, and PKC α activation or inhib-
ition might affect the proliferation and survival of cancer
cells [4,6,7].
After transiently transfecting PKC siRNA into the
bladder cancer T24 and BIU-87 cells, it clarified PKC
α’s regulatory mechanismson on netrin-1/UNC5B; Real-
time PCR test results showed that netrin-1 was inhibited
after PKC siRNA transfection, with its expression de-
creased, while UNC5B increased. Immunofluorescence
Figure 9 Detection of cell cycle by flow cytometry. (A) Flow cytometry was used to examine BIU cell cycle. G1 / G2, S, G2/M phase occupied
57.19%, 13.14%, 16.72%, respectively. (B) & (C) With the increasing treatment time (24 h, 48 h) of PMA, the number of BIU cells increased
gradually in S phase and G2/M phase, and S phase was 22.33% for 24 h, 36.41% for 48 h; G2/M phase was 23.39% for 24 h, 34.42% for 48 h.
(D) & (E) With the increasing treatment time (24 h, 48 h) of calphostin C, the number of BIU cells decreased noticeably in S phase and G2/M
phase, and S phase was 8.39% for 24 h, 4.92% for 48 h; G2/M phase was 10.55% for 24 h, 7.46% for 48 h. The data are representative of 3
individual experiments. (F) Summary of cell cycle distribution in panel A-E.
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α with UNC5B expression. So we speculate that there
may be endogenous binding.
From the above results, we can conclude that: PKC α
can promote bladder cancer cell proliferation through theFigure 10 Migration and invasion assays were used by wound healing
verify the invasion capability of the prostate carcinoma cells. Results showed tregulation of netrin-1/UNC5B. On this basis, we can
intervene any stage in which PKC α and netrin-1/UNC5B
affect, so as to control the proliferation of bladder cancer,
and provide adequate theoretical basis for bladder cancer’s
diagnosis and treatment.in BC cells (SV, 5637, BIU, T24). Comparing scratches width in order to
hat the most invasive cells were T24 and all BC cells were invasive.
Figure 11 PKC siRNAs were transfected into bladder cancer cells T24 & BIU-87 transiently. Real-time PCR results found after transfection
PKC siRNA, netrin-1 was inhibited and the expression was decreased, while UNC5B was activated and the expression was elevated.
Figure 12 The confocal immunofluorescence displayed that the existence of co-localization expression of PKC α and UNC5B. Results
showed that PKC α (green) and UNC5B (red) were observed and a co-localization expression of PKC α and UNC5B could be observed (yellow).
Nuclear staining was performed with DAPI (blue) in panels.
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